Novel prodromal biomarkers that are symptomatic of injury require histopathologic or clinical chemistry anchors to characterize activity.
Ozer
Josef S
JS
Pfizer Global Research and Development, Pharmacokinetics, Dynamics, and Metabolism, 700 Chesterfield Parkway West, T2A, Chesterfield, MO 63017, USA. josef.ozer@pfizer.com
Teitelbaum
Aaron
A
D000208:Acute Disease; D000818:Animals; D015415:Biomarkers / Q000378:metabolism / Q000652:urine; D002624:Chemistry, Clinical / Q000379:methods / Q000592:standards; D006719:Homovanillic Acid / Q000652:urine; D006801:Humans; D007674:Kidney Diseases / Q000209:etiology* / Q000378:metabolism* / Q000473:pathology / Q000652:urine
D015415:Biomarkers; D006719:Homovanillic Acid